Norway· NO-ID_88602014-79CA-4A37-9158-DD5957E52372
Simulect
A basiliximab product containing basiliximab, registered in Norway by Novartis Europharm Limited (1). The same ATC class is registered in 14 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Basiliximab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC02 (basiliximab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Basiliximab · ATC L04AC02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Basiliximab
- Manufacturer
- Novartis Europharm Limited (1)
- Country
- Norway (NO)
- ATC code
- L04AC02
- ATC class
- Basiliximab
- Defined daily dose
- 40 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_88602014-79CA-4A37-9158-DD5957E52372
- no_varenummer5227061NOK 13916.4
- gtin7612797497661
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
60 interactions on record for basiliximab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Basiliximab · interactions on record
60 records
- 27 severe
- 26 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Basiliximab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandSimulectNovartis Europharm Limited
- SwitzerlandSimulect 20 mg, Pulver und Lösungsmittel zur Herstellung einer Injektions-/InfusionslösungNovartis Pharma Schweiz AG
- BelgiumSimulect 20 mgNovartis Europharm
- IcelandSimulectNovartis Europharm Limited*
- SwedenSimulect 20 mg Pulver och vätska till injektions-/infusionsvätska, lösningNovartis Europharm Limited
- PolandSimulectNovartis Europharm Limited
- CzechiaSIMULECTNovartis Europharm Limited, Dublin
- IrelandSimulect 20 mg powder and solvent for solution for injection or infusionNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Simulect
- Liechtenstein · Simulect
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a6a7db23-e4df-4830-8646-051ec98ae8e9 GET /v1/drugs/a6a7db23-e4df-4830-8646-051ec98ae8e9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver og væske til injeksjons-/infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Basiliksimab",
"merkevare_id": "ID_88602014-79CA-4A37-9158-DD5957E52372",
"name_form_strength": "Simulect pulv+væske til inj/inf oppl 20 mg",
"prescription_group": "C"
}See everything about basiliximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.